336: Comparison of misoprostol vaginal insert and dinoprostone vaginal insert: incidence of treatment-emergent adverse events

Abstract

To compare the incidence of treatment-emergent adverse events (TEAEs) experienced by women treated with either controlled-release misoprostol vaginal insert 200 mcg (MVI 200) or dinoprostone vaginal insert 10 mg (DVI).